144 related articles for article (PubMed ID: 18316567)
1. IFN-alpha-2b-induced signal transduction and gene regulation in patient peripheral blood mononuclear cells is not enhanced by a dose increase from 5 to 10 megaunits/m2.
Zimmerer JM; Lehman AM; Ruppert AS; Noble CW; Olencki T; Walker MJ; Kendra K; Carson WE
Clin Cancer Res; 2008 Mar; 14(5):1438-45. PubMed ID: 18316567
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy.
Lesinski GB; Kondadasula SV; Crespin T; Shen L; Kendra K; Walker M; Carson WE
J Natl Cancer Inst; 2004 Sep; 96(17):1331-42. PubMed ID: 15339971
[TBL] [Abstract][Full Text] [Related]
3. Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells.
Lesinski GB; Trefry J; Brasdovich M; Kondadasula SV; Sackey K; Zimmerer JM; Chaudhury AR; Yu L; Zhang X; Crespin TR; Walker MJ; Carson WE
Clin Cancer Res; 2007 Sep; 13(17):5010-9. PubMed ID: 17785551
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12.
Eisenbeis CF; Lesinski GB; Anghelina M; Parihar R; Valentino D; Liu J; Nadella P; Sundaram P; Young DC; Sznol M; Walker MJ; Carson WE
J Clin Oncol; 2005 Dec; 23(34):8835-44. PubMed ID: 16314644
[TBL] [Abstract][Full Text] [Related]
5. The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.
Martin del Campo SE; Levine KM; Mundy-Bosse BL; Grignol VP; Fairchild ET; Campbell AR; Trikha P; Mace TA; Paul BK; Jaime-Ramirez AC; Markowitz J; Kondadasula SV; Guenterberg KD; McClory S; Karpa VI; Pan X; Olencki TE; Monk JP; Mortazavi A; Tridandapani S; Lesinski GB; Byrd JC; Caligiuri MA; Shah MH; Carson WE
J Immunol; 2015 Sep; 195(5):1995-2005. PubMed ID: 26238487
[TBL] [Abstract][Full Text] [Related]
6. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
[TBL] [Abstract][Full Text] [Related]
7. Interferon alpha and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects.
Brown L; Roda J; Terrell C; Chaudhury AR; Crespin T; Carson WE; Lesinski GB
Surgery; 2006 Aug; 140(2):297-306. PubMed ID: 16904983
[TBL] [Abstract][Full Text] [Related]
8. Type III Interferon Induces Distinct SOCS1 Expression Pattern that Contributes to Delayed but Prolonged Activation of Jak/STAT Signaling Pathway: Implications for Treatment Non-Response in HCV Patients.
Liu B; Chen S; Guan Y; Chen L
PLoS One; 2015; 10(7):e0133800. PubMed ID: 26193702
[TBL] [Abstract][Full Text] [Related]
9. IL-12 pretreatments enhance IFN-alpha-induced Janus kinase-STAT signaling and potentiate the antitumor effects of IFN-alpha in a murine model of malignant melanoma.
Lesinski GB; Badgwell B; Zimmerer J; Crespin T; Hu Y; Abood G; Carson WE
J Immunol; 2004 Jun; 172(12):7368-76. PubMed ID: 15187113
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.
Varker KA; Biber JE; Kefauver C; Jensen R; Lehman A; Young D; Wu H; Lesinski GB; Kendra K; Chen HX; Walker MJ; Carson WE
Ann Surg Oncol; 2007 Aug; 14(8):2367-76. PubMed ID: 17534686
[TBL] [Abstract][Full Text] [Related]
12. Interferon-alpha-induced activation of signal transducer and activator of transcription proteins in malignant melanoma.
Carson WE
Clin Cancer Res; 1998 Sep; 4(9):2219-28. PubMed ID: 9748142
[TBL] [Abstract][Full Text] [Related]
13. [ISGF3, a critical factor of the IFN-alpha pathway in the antiviral action of HBV].
Zhang Q; Wei L; Wang Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Jun; 19(2):110-3. PubMed ID: 16027772
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
Richtig E; Hofmann-Wellenhof R; Pehamberger H; Forstinger Ch; Wolff K; Mischer P; Raml J; Fritsch P; Zelger B; Ratzinger G; Koller J; Lang A; Konrad K; Kindermann-Glebowski E; Seeber A; Steiner A; Fialla R; Pachinger W; Kos C; Klein G; Kehrer H; Kerl H; Ulmer H; Smolle J
Br J Dermatol; 2004 Jul; 151(1):91-8. PubMed ID: 15270876
[TBL] [Abstract][Full Text] [Related]
15. Reduction in p48-ISGFgamma levels confers resistance to interferon-alpha2a in MHCC97 cells.
Wu WZ; Sun HC; Gao YQ; Li Y; Wang L; Zhou K; Liu KD; Iliakis G; Tang ZY
Oncology; 2004; 67(5-6):428-40. PubMed ID: 15714000
[TBL] [Abstract][Full Text] [Related]
16. IFN-gamma priming up-regulates IFN-stimulated gene factor 3 (ISGF3) components, augmenting responsiveness of IFN-resistant melanoma cells to type I IFNs.
Wong LH; Hatzinisiriou I; Devenish RJ; Ralph SJ
J Immunol; 1998 Jun; 160(11):5475-84. PubMed ID: 9605150
[TBL] [Abstract][Full Text] [Related]
17. Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (Stat1).
Chawla-Sarkar M; Leaman DW; Jacobs BS; Tuthill RJ; Chatterjee-Kishore M; Stark GR; Borden EC
J Interferon Cytokine Res; 2002 May; 22(5):603-13. PubMed ID: 12060499
[TBL] [Abstract][Full Text] [Related]
18. The Study of Immune Response in PBMC of CHB Patients treated with IFN-α and 3-TC in vitro.
Zhang H; Guan ZS; Guan SH; Yang K; Pan Y; Wu YY; Wang AH; Sun BB; Hou J; Mu XX; Gao YF; Cheng WS
Clin Lab; 2016 Dec; 62(12):2313-2318. PubMed ID: 28164560
[TBL] [Abstract][Full Text] [Related]
19. Global changes in STAT target selection and transcription regulation upon interferon treatments.
Hartman SE; Bertone P; Nath AK; Royce TE; Gerstein M; Weissman S; Snyder M
Genes Dev; 2005 Dec; 19(24):2953-68. PubMed ID: 16319195
[TBL] [Abstract][Full Text] [Related]
20. Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2.
Leaman DW; Chawla-Sarkar M; Jacobs B; Vyas K; Sun Y; Ozdemir A; Yi T; Williams BR; Borden EC
J Interferon Cytokine Res; 2003 Dec; 23(12):745-56. PubMed ID: 14769151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]